Serum insulin-like growth factor

KHALIL D A, LUCAS E A, lUMA S, SMITH B J, PAYTON M E and ARJMANDI B H (2002) Soy prOteiu supplementation increases serum insulin-like growth factor-1 in young and old men but does not affect markers of bone metabolism. J Nutr 132, 2605-8. 

Li, L, H Ya, F Schumacher, G Casey, and JS Witte. 2003. Relations of serum insulin-like growth factor-1-(IGF-1) and IGF binding protein-3 to risk of prostate cancer(United States). Cancer Causes Control 14 721-726. 

Miyata, Y, H Sakai, T Hayashi, and H Kanetake. 2003. Serum insulin-like growth factor binding protein-3/ prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 54 125-132. 

Parkinson, C., Kassem, M., Heickendorff, L., et al. PEGvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J. Clin. Endocrinol. Metab. 88(12) 5650-5655. 2003. 

Selegiline possesses cognition-enhancing function, rejuvenates serum insulin-like growth factor I in aging humans and enhances life expectancy. 

RESTORATION BY SELEGILINE OF SERUM INSULIN-LIKE GROWTH FACTOR-1 IN AGED RATS... 

R8a. Rudman D., Mattson, O., Serum insulin-like growth factor 1 in healthy older men in relation to physical activity. J. Am. Geriatr. Soc. 42,71—76 (1994). 

G5. Garnero, P., Tsouderos, Y., Marton, I., Pelissier, C., Varin, C., and Delmas, P. D., Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J. Clin. Endocrinol. Metab. 84, 2390-2397 (1999). 

Baffa, R., Reiss, K., El-Gabry, E.A., Sedor, J. et al.. Low serum insulin-like growth factor 1 (lGF-1) a significant association with prostate cancer. Tech. Urol, 6, 236-239, 2000. 

Townsend L, Ongjni E, Wenk G (2004) Novel therapeutic opportunities for Alzheimer s disease focus on nonsteroidal anti-inflammatory drugs. FASEB J 19 1592-1601 Trejo JL, Cairo E, Nunez A, Torres-Aleman 1 (2002) Sedentary hfe impairs self-reparative processes in the brain the role of serum insulin-like growth factor-1. Rev Neurosci 13 365-374 Tsuboi Y, Doh-ura K, Yamada T (2009) Continuous intraventricular infusion of pentosan polysulfate clinical trial against prion diseases. Neuropathology 29(5) 632-636 Tsujimoto Y, Shimizu S (2003) Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 12 835-840... 

ARJMANDI B H, KHALIL D A and HOLLIS B w (2002), Soy protein its effects on intestinal calcium transport, serum vitamin D and insulin-like growth factor-1 in ovariectomized rats. Calcif Tissue Int 70(6), 483-7. 

Riso, P, A Brusamolino, A Martinetti, and M Porrini. 2006. Effect of a tomoto drink intervention on insulin-like growth factor (IGF)-l serum levels in health subjects. Nutr Cancer 55(2) 157-162. 

The presence of serum-binding proteins. Some biopharmaceuticals (including insulin-like growth factor (IGF), GH and certain cytokines) are notable in that the blood contains proteins that specifically bind them. Such binding proteins can function naturally as transporters or activators, and binding can affect characteristics such as serum elimination rates. 

Thrailkill KM, Fowlkes JL, Hyde JF, Litton JC. The effects of co-therapy with recombinant human insulin-like growth factor I and insulin on serum leptin levels in adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2001 2(l) 25-9. 

P. J. De Bleser, C. D. Scott, T. Niki, G. Xu, E. Wisse, and A. Geerts, Insulin-like growth factor II/mannose 6-phosphate-receptor expression in liver and serum during acute CC14 intoxication in the rat, Hepatology 23 1530-1537 (1996). 

Daughaday WH, Rotwein P (1989), Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations, Endocr. Rev. 10 68-91. 

Serum growth hormone levels were dose-dependently increased after oral and intravenous administration. Moreover, an increase of insulin-like growth factor and serum cortisol was found. Clearly, the pituitary incubation method can only identify compounds which are suitable for further in vivo characterization, because the responses found in test animals at the target organ level are vast different from those found at the pituitary cell level. 

Jl. Jehle, P. M., Jehle, D. R., Mohan, S., andBohm, B. O., Serum levels of insulin-like growth factor system components and relatioship to bone metabolism in type 1 and type 2 diabetes meflitus patients. J. Endocrinol. 159, 297-306 (1998). 

Salobir, B., Prezelj, J., Meden-Vrtovec, H., Kocijanic, A., and Osredkar, J., Insulin-like growth factor binding protein-3 (IGFBP-3) serum concentrations and ovarian responsiveness in in-vitro fertilization. Hum. Reprod. 11, 2208-2210 (1996). 

Baxter RC. Insulin-like growth factor (IGF) binding proteins The role of serum IGFBPs in regulating IGF availability. Acta Paediatr Scand Suppl 1991 372 107-14. 

Lopez-Calderon A, Soto L, Villanua MA, Vidarte L, Martin AI. The effect of cyclosporine administration on growth hormone release and serum concentrations of insulin-like growth factor-I in male rats. Life Sci 1999 64(17) 1473-83. 

M. Costello, R. C. Baxter, and C. D. Scott, Regulation of soluble insulin-like growth factor II mannose 6-phosphate receptor in human serum Measurement by enzyme-linked immunosorbent assay, J. Clin. Endocrinol. Metab. 84 611 (1999). 

---